This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Erin Jones Biography and Net Worth

Insider of Gritstone bio

Erin E. Jones, M.S., is the chief operating officer. He had served as Gritstone’s executive vice president of global regulatory affairs and quality since May 2016. Prior to Gritstone, from July 2014 to April 2016, Mr. Jones served as vice president, global head of regulatory affairs, medical writing, pharmacology and toxicology at Puma Biotechnology, Inc., or Puma, a public biopharmaceutical company. Prior to Puma, Mr. Jones served as director, regulatory affairs at BioMarin Pharmaceutical Inc. from July 2012 to July 2014. Earlier in his career, Mr. Jones held various positions at Genentech, Inc., or Genentech, a biotechnology corporation and subsidiary of Roche, including head of regulatory intelligence and leader of the HER Franchise Regulatory Group. Mr. Jones received a B.S. in microbiology and chemistry from the University of Pittsburgh and an M.S. in computer systems from Pennsylvania State University.

What is Erin E. Jones' net worth?: The estimated net worth of Erin E. Jones is at least $0.00 as of May 16th, 2024. Mr. Jones owns 359,293 shares of Gritstone bio stock worth more than $0 as of November 16th. This net worth evaluation does not reflect any other investments that Mr. Jones may own. Additionally, Mr. Jones receives an annual salary of $689,870.00 as Insider at Gritstone bio. Learn More about Erin E. Jones' net worth.
How old is Erin E. Jones?: Mr. Jones is currently 52 years old. There are 4 older executives and no younger executives at Gritstone bio. The oldest executive at Gritstone bio is Dr. Karin Jooss Ph.D., Executive VP and Head of Research & Development, who is 59 years old. Learn More on Erin E. Jones' age.
What is Erin E. Jones' salary?: As the Insider of Gritstone bio, Inc., Mr. Jones earns $689,870.00 per year. There are 2 executives that earn more than Mr. Jones. The highest earning executive at Gritstone bio is Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,010,000.00 per year. Learn More on Erin E. Jones' salary.
How do I contact Erin E. Jones?: The corporate mailing address for Mr. Jones and other Gritstone bio executives is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. Gritstone bio can also be reached via phone at (510) 871-6100 and via email at [email protected]. Learn More on Erin E. Jones' contact information.
Has Erin E. Jones been buying or selling shares of Gritstone bio?: Erin E. Jones has not been actively trading shares of Gritstone bio during the past quarter. Most recently, Erin Jones sold 13,749 shares of the business's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $0.75, for a transaction totalling $10,311.75. Following the completion of the sale, the chief operating officer now directly owns 359,293 shares of the company's stock, valued at $269,469.75. Learn More on Erin E. Jones' trading history.
Are insiders buying or selling shares of Gritstone bio?: In the last year, insiders at the sold shares 3 times. They sold a total of 47,271 shares worth more than $35,453.25. The most recent insider tranaction occured on May, 16th when COO Erin Jones sold 13,749 shares worth more than $10,311.75. Insiders at Gritstone bio own 4.6% of the company. Learn More about insider trades at Gritstone bio.
Information on this page was last updated on 5/16/2024.

Erin E. Jones Insider Trading History at Gritstone bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/16/2024	Sell	13,749	$0.75	$10,311.75	359,293
12/1/2021	Sell	1,000	$13.01	$13,010.00
11/1/2021	Sell	1,000	$11.14	$11,140.00

Erin E. Jones Buying and Selling Activity at Gritstone bio

Gritstone bio Company Overview

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Today's Range

Now: N/A

50 Day Range

MA: $0.36

$0.03

$0.63

2 Week Range

Now: N/A

Volume

61,017,900 shs

Average Volume

7,014,435 shs

Market Capitalization

$3.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad